PepGen, Inc. (NASDAQ:PEPG) Receives Average Rating of “Moderate Buy” from Analysts

Shares of PepGen, Inc. (NASDAQ:PEPG) have been given a consensus rating of “Moderate Buy” by the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $11.50.

Several analysts have recently weighed in on PEPG shares. Wall Street Zen upgraded PepGen from a “sell” rating to a “hold” rating in a research report on Sunday, June 7th. Weiss Ratings downgraded PepGen from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 2nd. HC Wainwright reiterated a “buy” rating on shares of PepGen in a research report on Thursday, May 21st. Craig Hallum started coverage on PepGen in a research report on Tuesday, June 16th. They set a “buy” rating and a $11.00 target price for the company. Finally, Wedbush decreased their target price on PepGen from $5.00 to $4.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th.

PepGen Trading Down 0.6%

PEPG opened at $1.70 on Friday. The firm has a market cap of $117.59 million, a P/E ratio of -0.97 and a beta of 1.93. PepGen has a 12 month low of $1.01 and a 12 month high of $7.80. The stock has a 50-day moving average of $1.60 and a 200 day moving average of $3.93.

PepGen (NASDAQ:PEPG) last announced its earnings results on Tuesday, May 12th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05. On average, research analysts forecast that PepGen will post -1.2 earnings per share for the current fiscal year.

Institutional Trading of PepGen

A number of large investors have recently modified their holdings of the company. RA Capital Management L.P. boosted its holdings in shares of PepGen by 87.7% in the third quarter. RA Capital Management L.P. now owns 20,064,545 shares of the company’s stock valued at $92,698,000 after purchasing an additional 9,375,000 shares during the period. Commodore Capital LP boosted its holdings in shares of PepGen by 31.6% in the first quarter. Commodore Capital LP now owns 4,475,000 shares of the company’s stock valued at $7,921,000 after purchasing an additional 1,075,000 shares during the period. Viking Global Investors LP boosted its holdings in shares of PepGen by 134.9% in the third quarter. Viking Global Investors LP now owns 3,482,434 shares of the company’s stock valued at $16,089,000 after purchasing an additional 2,000,000 shares during the period. Vivo Capital LLC purchased a new stake in shares of PepGen in the third quarter valued at approximately $10,742,000. Finally, Laurion Capital Management LP boosted its holdings in shares of PepGen by 8.5% in the fourth quarter. Laurion Capital Management LP now owns 2,052,133 shares of the company’s stock valued at $13,359,000 after purchasing an additional 159,977 shares during the period. Hedge funds and other institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).